Zymeworks (FRA:ZA8) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ZA8 Zymeworks Inc FRA:ZA8
59 GF Score
Price €20.41
GF Value €21.84
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Zymeworks Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Zymeworks's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

FRA:ZA8 vs SRPT, BCAX, INVA: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Zymeworks's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zymeworks Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Zymeworks's Margin of Safety % (DCF Dividends Based) falls into.


FRA:ZA8
59GF Score
Zymeworks Inc FRA:ZA8
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zymeworks (FRA:ZA8) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be undervalued. The current stock price of €20.41 is trading 6.5% below its estimated GF Value™ of €21.84. GuruFocus considers Zymeworks to be Fairly Valued.

Key valuation signals for FRA:ZA8:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €21.84 vs. price of €20.41 (6.5% below fair value)
  • GF Score™: 59/100 with 2 warning signs

No single metric tells the full story. See the FRA:ZA8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZYME:USAZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
59GF Score

Get the complete analysis for FRA:ZA8

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.41
Price
€21.84
GF Value